EPIREAD
Live / Allowed — Notice of allowance issued (as of 24 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 02 Feb 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98388189
- Mark type
- Stylized text
- Filed
- 02 Feb 2024
- Published for opposition
- 07 Jan 2025
- Attorney of record
- Michael J. Allan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pulmonary, renal, reproductive, respiratory, and skeletal diseases, and age-related diseases in the nature of arthritis, thyroid imbalance, heart disease, kidney disease, cancer, endocrine disorders, liver disease, obesity, skin, respiratory, gastrointestinal and dental disease
Owner
- Moonwalk Biosciences, South San Francisco, CA, US
- Moonwalk Biosciences, South San Francisco, CA, US
Prosecution history
- 24 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Jan 2026 — NEW NOA TO ISSUE
- 13 Jan 2026 — NOTICE OF ALLOWANCE CANCELLED
- 06 Jan 2026 — NOTICE OF REVIVAL - E-MAILED
- 06 Jan 2026 — PETITION TO REVIVE-GRANTED
- 06 Jan 2026 — TEAS PETITION TO REVIVE RECEIVED
- 06 Jan 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 05 Jan 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 05 Jan 2026 — CORRECTED NOA E-MAILED
- 05 Jan 2026 — DIVISIONAL PROCESSING COMPLETE
- 11 Jul 2025 — DIVISIONAL REQUEST RECEIVED
- 05 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Jul 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 04 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED